HEALTHCARE

May 23, 2019

India Doctors Forum (IDF), Kuwait organized its 16th annual Ghabqa celebration on 19th May at the Regency Hotel. Deputy Chief of Mission at the Indian Embassy, Raj Gopal Singh graced the occasion as the Chief Guest, while the President of Kuwait Medical Association (KMA) Dr. Ahmed Thuwaini Al Enezi was the Guest of Honour.

Other"... Continue Reading

May 23, 2019

KUWAIT: Chairman of Kuwait Association of Surgeons and the head of Jaber Hospital’s surgery department Dr Salman Al-Sabah said 200 surgeries had been conducted at the hospital since January. Speaking to reporters on the sidelines of a ghabqa, he stressed that Jaber Hospital is meant to become the best in the region, adding that all surgical majors had started in the hospital. He warned of the growing"... Continue Reading

May 22, 2019

Remote monitoring and patient self-monitoring can drive CPAP adherence for people with sleep apnea, according to research presented by ResMed (NYSE: RMD) (ASX: RMD) at the American Thoracic Society’s 2019 ATS International Conference.

Average adherence to PAP (positive airway pressure), the gold standard for treating sleep"... Continue Reading

May 21, 2019

KUWAIT CITY, May 20, (KUNA): Minister of Health Sheikh Dr Bassel Al-Sabah said Monday that medicine stock in the ministry is sufficient for six months.

Speaking to reporters at parliament, the minister stated that the emergency plan prepared by the"... Continue Reading

May 21, 2019

(AETOS Wire) -- Masimo (NASDAQ: MASI) announced today the results of a study published in BMC Anesthesiology in which clinicians at Peking Union Medical College in Beijing evaluated the ability of noninvasive and continuous hemoglobin monitoring with Masimo SpHb® to help clincians estimate when to conduct invasive hemoglobin measurement to detect possible anemia in patients undergoing spine or cytoreductive surgery.1 Noting that because of the “invasive, time-consuming and intermittent” nature of invasive blood sampling, clincians often forgo these “objective indications” when making transfusion decisions during surgery, Dr. Tang and colleagues sought to determine whether noninvasive, continuous hemoglobin monitoring could aid clinicians in estimating when it might be appropriate to perform an invasive measurement. They enrolled...... Continue Reading

May 20, 2019

• Results of pivotal Phase III SENSCIS® trial published today in the New England Journal of Medicine (NEJM) and presented at the American Thoracic Society Conference in Dallas, USA
• Interstitial lung disease (ILD) is a key driver of mortality in people living with systemic sclerosis (SSc) – also known as scleroderma – and the absence of approved treatment options constitutes a high unmet need2,3
• FDA grants priority review to application... Continue Reading

May 20, 2019

(AETOS Wire) -- ResMed (NYSE: RMD, ASX: RMD) today revealed several demographic and clinical factors affect adherence to PAP (positive airway pressure) therapy, according to a study it presented at the American Thoracic Society's ATS 2019 International Conference.

The study found significant"... Continue Reading

May 20, 2019

(AETOS Wire) -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) today announced that the company will present data at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 31-June 4 in Chicago and the 24th Congress of the European Hematology Association (EHA), June 13-16 in Amsterdam. “We look forward to presenting data at ASCO and EHA that illustrate the continued progress of our portfolio in both clinical research and real-world settings in solid tumors and blood cancers,” said Phil Rowlands, Ph.D., Head, Oncology Therapeutic Area Unit, Takeda. “These data demonstrate our continued commitment to the discovery, development and delivery of medicines for patients with cancers.” At ASCO, Takeda will present data from both its lung portfolio and hematology portfolio. Results from a Phase 1/2 first-in-human,...... Continue Reading

May 20, 2019

(AETOS Wire)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced further results from the Phase 3b head-to-head VARSITY study, which demonstrated that the gut-selective biologic vedolizumab (Entyvio®) was superior to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira®) in achieving clinical remission* at week 52 in patients with moderately to severely active ulcerative colitis (UC).1 New exploratory data showed that a greater proportion of patients receiving vedolizumab intravenous (IV) achieved clinical response** at week 14 compared to those treated with adalimumab subcutaneous (SC), 67.1% vs. 45.9% respectively. A separation between the treatment groups was seen as early as week 6, favoring vedolizumab. These results were announced in a Distinguished Abstract Plenary...... Continue Reading

May 18, 2019

KUWAIT CITY, May 16: The first smart hospital in Kuwait will be opened within a few months, reports Al-Anba daily. Director of the Infectious Diseases Hospital Dr Jamal Al-Duaij revealed about the endeavor and a plan to equip the new building of Infectious Diseases Hospital in order for it to become the first smart hospital of its kind in Kuwait. In a press statement, he said, “We hope the ministry"... Continue Reading